Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT00898833
What this trial is testing

Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 868
Testing effectiveness (Phase 2)Study completedNCT00433446
What this trial is testing

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
SWOG Cancer Research Network 62
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Early research (Phase 1)Study completedNCT01324583
What this trial is testing

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 48
Testing effectiveness (Phase 2)UnknownNCT00215345
What this trial is testing

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer

Who this might be right for
Prostate Cancer
Department of Veterans Affairs, New Jersey 66
Testing effectiveness (Phase 2)Ended earlyNCT01020305
What this trial is testing

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerProstatic NeoplasmsCastrate-resistant Prostate Cancer (CRPC)+3 more
Sandy Srinivas 5
Testing effectiveness (Phase 2)Study completedNCT01897207
What this trial is testing

Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer

Who this might be right for
Cancer of the Prostate
Cantonal Hospital of St. Gallen 15
Early research (Phase 1)Study completedNCT01295632
What this trial is testing

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Who this might be right for
Advanced Cancer
Merck Sharp & Dohme LLC 65
Early research (Phase 1)Study completedNCT00215709
What this trial is testing

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Geriatric Oncology Consortium 17
Testing effectiveness (Phase 2)Study completedNCT00004045
What this trial is testing

Chemotherapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00545766
What this trial is testing

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Prostate Cancer
SCRI Development Innovations, LLC 41
Testing effectiveness (Phase 2)Study completedNCT00072722
What this trial is testing

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Prostate Cancer
Celgene Corporation 36
Testing effectiveness (Phase 2)Study completedNCT00327340
What this trial is testing

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Who this might be right for
Prostate Cancer
Achieve Life Sciences 70
Testing effectiveness (Phase 2)Study completedNCT05848011
What this trial is testing

Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Androgen-Independent Prostatic CancerAndrogen-Independent Prostatic NeoplasmsProstate Cancer Recurrent+6 more
MacroGenics 154
Early research (Phase 1)Study completedNCT02152943
What this trial is testing

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor PositiveHER2/Neu Positive+10 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Study completedNCT00002503
What this trial is testing

Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases

Who this might be right for
Metastatic CancerProstate Cancer
European Organisation for Research and Treatment of Cancer - EORTC 204
Large-scale testing (Phase 3)Study completedNCT00036543
What this trial is testing

Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Abbott 1,000
Testing effectiveness (Phase 2)Study completedNCT00728663
What this trial is testing

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 35
Testing effectiveness (Phase 2)Study completedNCT00286806
What this trial is testing

Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Ascenta Therapeutics 27
Next Page